Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

• Status: Completed
• Trial end date: 2012-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Moderate to severe forehead lines

Exclusion Criteria:

• Current or previous botulinum toxin treatment of any serotype within one year

• Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis

• Prior facial cosmetic surgery (e.g. prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery)

• Facial laser or light treatment, microdermabrasion, or superficial peels within 3 months

• Oral retinoid therapy within one year